Anthem Grandfathered Rx Settlement
Up to $8,850
What happened
Anthem denied coverage for brand name prescription drugs or applied a deductible for brand name drugs under certain health plans, charging members up to an $8,850 deductible. The company settled with California's Department of Insurance to refund deductibles and reimburse members for out-of-pocket expenses on brand name prescriptions that should have been covered.
Do you qualify?
Anyone who was covered under Anthem's Core 5000, Tonik DN14, Tonik DN15, or RightPlan (with generic prescription drug coverage) between January 1, 2017 and May 8, 2026, and paid out of pocket for a brand name prescription drug that was denied solely because it was a brand name product, or who paid the $8,850 deductible for brand name drug coverage.
How to file
For out-of-pocket reimbursement, submit a completed claim form with all required supporting documentation postmarked by November 10, 2026. For deductible refunds, no claim form is needed—eligible members will automatically receive refunds mailed on May 22, 2026. Review the eligibility requirements and documentation checklist in the Notice and Claim Form package mailed on May 8, 2026.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More drugs & medical settlements
View all →QVAR Antitrust Settlement
Teva allegedly took unlawful actions to delay generic versions of QVAR asthma inhalers from entering the market, including improperly listing patents in the FDA's Orange Book and discontinuing versions to switch to new ones. These actions allegedly kept QVAR prices artificially high, causing consumers and insurers to overpay. Teva denies all allegations and maintains it did nothing wrong.
Tracleer Litigation Settlement
The Defendants allegedly unlawfully delayed the entry of generic formulations of bosentan into the market, causing third-party payors to pay more for brand Tracleer and bosentan than they should have. The Defendants deny they did anything wrong.
Metformin Marketing and Sales Practices Litigation Settlement
The defendants allegedly falsely advertised generic metformin drugs as equivalent to Glucophage and Glucophage XR, but the drugs were actually contaminated with N-nitrosodimethylamine (NDMA) and did not meet FDA standards. As a result, consumers and businesses paid for drugs they would not have purchased. The defendants deny any wrongdoing.
Polyclinic Compensation Fund Settlement
The Polyclinic allegedly failed to provide qualified interpreters necessary for effective communication with patients who have hearing, vision, and/or speech disabilities between January 1, 2021 and September 30, 2025. The U.S. Attorney's Office contends this violated the Americans with Disabilities Act (ADA). The Polyclinic denies wrongdoing and has agreed to pay $350,000 to resolve the investigation without further litigation.